Bosch Health Companies Inc. (NYSE:BHC – Get Rating) saw unusually heavy options trading on Friday. Traders acquired 65,845 call options on the company. This is an increase of about 253% compared to the normal volume of 18,678 call options.
Analyst Rating Changes
→ Bombshell Economy Expo (from Porter & Company)
Separately, StockNews.com initiated coverage on Bosch Health Companies in a research report on Wednesday, October 12. He issued a “Hold” rating on the stock. Five research analysts have a hold rating on the stock, according to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $10.60.
Bosch Health Companies is trading up 4.9%
Shares of Bosch Health Companies traded up $0.38 to $8.15 during midday trading on Friday. The company had a trading volume of 7,917,339 shares as compared to an average volume of 4,648,187. Bosch Health Companies has a 52 week low of $4.00 and a 52 week high of $26.39. The company has a debt-to-equity ratio of 48.05, a current ratio of 1.05 and a quick ratio of 0.77. The fifty-day moving average price of the stock is $7.15 and the 200-day moving average price is $6.99. The firm has a market cap of $2.95 billion, a PE ratio of 11.64, a P/E/G ratio of 0.11, and a beta of 0.96.
Bosch Health Companies (NYSE:BHC — Receive Rating) issued its quarterly earnings results last Thursday, November 3. The company reported earnings per share (EPS) of $0.76 for the quarter, missing the consensus estimate of $0.92 ($0.16). Bosch Health Companies had a net margin of 3.13% and a return on equity of 942.47%. The business had revenue of $2.05 billion during the quarter, compared to analyst estimates of $2.09 billion. On average, equity analysts expect Bosch Health Companies to earn Rs 2.97 earnings per share for the current year.
Institutional investors weigh up on Bosch Health Companies
Hedge funds and other institutional investors have recently modified their holdings of the company. Wipfly Financial Advisors LLC bought a new position in Bosch Health Companies in the third quarter worth $25,000. Optivar Holding BV increased its position in shares of Bosch Health Companies to 707.6% during the third quarter. Optiver Holding BV now owns 4,054 shares of the company’s stock valued at $28,000 after purchasing an additional 3,552 shares during the last quarter. Pacifica Partners Inc. Shares of Bosch Health Companies soared 2,232.6% during the fourth quarter. Pacifica Partners Inc. now owns 5,015 shares of the company’s stock valued at $31,000 after purchasing an additional 4,800 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of Bosch Health Companies to 420.1% during the third quarter. Quadrant Capital Group LLC now owns 5,851 shares of the company’s stock valued at $40,000 after purchasing an additional 4,726 shares during the last quarter. Lastly, First Horizon Advisors Inc. Shares of Bosch Health Companies soared 85.1% during the second quarter. First Horizon Advisors Inc. after buying an additional 2,578 shares during the last quarter. now owns 5,607 shares of the company’s stock valued at $45,000. Institutional investors hold 66.99% of the company’s stock.
About Bosch Health Companies
Bausch Health Company Inc., together with its subsidiaries, develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics and Diversified Products.
This instant news alert was generated by descriptive science technology and financial data from MarketBeat to provide readers the fastest and most accurate reporting. This story was reviewed by Marketbeat’s editorial team before publication. Please send any questions or comments about this story to [email protected]
Before you consider Bosch Health Companies, you may want to hear this.
MarketBeat tracks Wall Street’s top rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified five stocks that top analysts are quietly whispering to their clients to buy, before the broader market catches on… and Bosch Health Companies wasn’t on the list.
While Bosch Health Companies currently has a “hold” rating among analysts, top rated analysts believe these five stocks are the better buys.
see five stocks here